Session » (0731–0764) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Date: Sunday, October 26, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 0735

A Real-World Study from the Greater Paris Clinical Data Warehouse

10:30AM-12:30PM: Abstract Number: 0744

Age and Sex Influence on Clinical Manifestations of Giant Cell Arteritis: Results from the ARTESER Registry

10:30AM-12:30PM: Abstract Number: 0758

Association Between Baseline IL-6 Levels and the Clinical Phenotype of Giant Cell Arteritis

10:30AM-12:30PM: Abstract Number: 0732

Blocking GM-CSF receptor alpha with mavrilimumab reduces production of growth factors involved in vascular remodeling in an ex-vivo model of temporal artery culture from patients with giant-cell arteritis (GCA)

10:30AM-12:30PM: Abstract Number: 0733

Cerebrovascular Accidents in Patients with Giant Cell Arteritis: A Population-Based Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 0741

Characteristics of African American vs. Non-African American Patients with Giant Cell Arteritis: A Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 0752

Characterization of patients with polymyalgia rheumatica in the ARTESER giant cell arteritis cohort

10:30AM-12:30PM: Abstract Number: 0763

Diagnostic Utility of Temporal Artery Biopsy in Giant Cell Arteritis: A Single Center Experience

10:30AM-12:30PM: Abstract Number: 0759

Distinct differences between giant cell arteritis diagnosed by fluorodeoxyglucose (FDG) positron emission tomography (PET) versus temporal artery biopsy-a comparative cohort study

10:30AM-12:30PM: Abstract Number: 0748

Does The Number Of Arteries Affected At The Disease Onset Predict Relapses Of Giant Cell Arteritis?

10:30AM-12:30PM: Abstract Number: 0737

Effectiveness and Safety of Janus Kinase Inhibitors in Giant Cell Arteritis. Real-World Clinical Practice Study and Literature Review

10:30AM-12:30PM: Abstract Number: 0736

Effectiveness of Tocilizumab in strokes in patients with giant cell arteritis. Spanish multicenter study of clinical practice

10:30AM-12:30PM: Abstract Number: 0742

Exploring Racial Variation in the Clinical Manifestations of Giant Cell Arteritis: A Retrospective Single-Center Study

10:30AM-12:30PM: Abstract Number: 0761

Fast-Track Clinics Improve Visual Outcomes in Giant Cell Arteritis: A Meta-Analysis

10:30AM-12:30PM: Abstract Number: 0750

Fibrinogen as a biomarker in the diagnosis of giant cell arteritis and detection of flares

10:30AM-12:30PM: Abstract Number: 0764

Frequency of large vessel vasculitis in giant cell arteritis with and without adventiitis of temporal artery – Is the presence of temporal arteritis sufficient to diagnose giant cell arteritis?-

10:30AM-12:30PM: Abstract Number: 0743

Giant Cell Arteritis Relapse After Treatment with Two Months of Prednisone and 12 Months of Tocilizumab

10:30AM-12:30PM: Abstract Number: 0734

Glucocorticoid Exposure and Comorbidity Profile in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: a multi-country cohort study

10:30AM-12:30PM: Abstract Number: 0746

Impact of Frailty on Mortality in GCA and PMR: A Retrospective Cohort

10:30AM-12:30PM: Abstract Number: 0751

Impact of Treatment with Upadacitinib on Biomarkers Identified by Proteomics in Giant Cell Arteritis

10:30AM-12:30PM: Abstract Number: 0753

Incidence of Ischemic Vision Loss Among Patients with Polymyalgia Rheumatica and Giant Cell Arteritis

10:30AM-12:30PM: Abstract Number: 0740

Intravenous versus subcutaneous administration of Tocilizumab in aortitis associated with giant cell arteritis: multicenter open-label study of 196 patients

10:30AM-12:30PM: Abstract Number: 0754

Is There a Seasonal Pattern in Giant Cell Arteritis? Revisiting the Evidence in a Large Monocentric Cohort of 1203 patients

10:30AM-12:30PM: Abstract Number: 0747

Patterns of Macrophage Polarization Induced by Serum from Patients with Giant Cell Arteritis and Takayasu’s Arteritis

10:30AM-12:30PM: Abstract Number: 0749

Prevalence and characteristics of subclinical Polymyalgia Rheumatica in patients with Giant Cell Arteritis

10:30AM-12:30PM: Abstract Number: 0745

Prevalence and Clinical Significance of Low ESR and CRP in Giant Cell Arteritis: A Population Based Study

10:30AM-12:30PM: Abstract Number: 0738

Real World Steroid Burden, Treatment Patterns, and Rheumatologists’ Perceptions on Advanced Therapy in Giant Cell Arteritis

10:30AM-12:30PM: Abstract Number: 0762

Relapse rate, predictors of relapses and impact of introduction of interleukin-6-receptor inhibition on relapse rate in GCA- Data from the large REATS cohort from six vasculitis centers

10:30AM-12:30PM: Abstract Number: 0755

Sex Differences in Subtypes of Vascular Involvement and Clinical Manifestations in Giant Cell Arteritis

10:30AM-12:30PM: Abstract Number: 0756

Stroke Characteristics in Giant Cell Arteritis and Takayasu Arteritis: A Multicenter Cohort Study of 108 Patients

10:30AM-12:30PM: Abstract Number: 0731

The Efficacy of Leflunomide in the Treatment of Giant Cell Arteritis: A Systematic Review and Meta-Analysis

10:30AM-12:30PM: Abstract Number: 0760

The Efficacy Of Targeted Therapies In Giant Cell Arteritis: A Systematic Review and Meta-Analysis

10:30AM-12:30PM: Abstract Number: 0757

The role of Methotrexate in the treatment of Giant Cell Arteritis: data from the ARTESER registry.

10:30AM-12:30PM: Abstract Number: 0739

Tocilizumab in Giant Cell Arteritis with ischemic vs non-ischemic manifestations

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].